CSIMarket
 
Tarsus Pharmaceuticals Inc   (TARS)
Other Ticker:  
 
 
Price: $36.9500 $-1.27 -3.323%
Day's High: $37.19 Week Perf: 11.43 %
Day's Low: $ 33.43 30 Day Perf: 35.65 %
Volume (M): 2,370 52 Wk High: $ 40.40
Volume (M$): $ 87,572 52 Wk Avg: $18.32
Open: $34.49 52 Wk Low: $11.33



 Market Capitalization (Millions $) 1,087
 Shares Outstanding (Millions) 29
 Employees -
 Revenues (TTM) (Millions $) 17
 Net Income (TTM) (Millions $) -136
 Cash Flow (TTM) (Millions $) 153
 Capital Exp. (TTM) (Millions $) 6

Tarsus Pharmaceuticals Inc
Tarsus Pharmaceuticals Inc is a biopharmaceutical company that specializes in developing and commercializing innovative therapies for ophthalmic diseases. The company aims to address unmet needs in the field of eye health by focusing on ocular surface and anterior segment conditions. Tarsus Pharmaceuticals is known for its expertise in the development of novel, small molecule therapeutics that target specific pathways involved in these diseases. The company's goal is to provide effective and safe treatment options to improve the lives of patients suffering from various eye disorders.


   Company Address: 15440 Laguna Canyon Road, Suite 160 Irvine 92618 CA
   Company Phone Number: 418-1801   Stock Exchange / Ticker: NASDAQ TARS
   TARS is expected to report next financial results on March 15, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Shares

Tarsus Pharmaceuticals Secures $100 Million Public Offering to Drive Innovation in Eye Care Sector

Published Fri, Mar 1 2024 5:08 AM UTC

Tarsus Pharmaceuticals Announces Pricing of $100 Million Public Offering
In a press release on March 1, 2024, Tarsus Pharmaceuticals, Inc. revealed the pricing of its underwritten public offering of 2,812,500 shares of common stock at $32.00 per share, as well as pre-funded warrants for an additional 312,500 shares at $31.9999. The company also granted the underwriters a...

Financing Agreement

Tarsus Pharmaceuticals Inc. Sets Stage for Transformational Growth with $100 Million Public Offering

Published Thu, Feb 29 2024 9:38 PM UTC



Tarsus Pharmaceuticals Inc., a pioneering biopharmaceutical company with a focus on transforming treatment options for patients, especially in the field of eye care, has announced the initiation of an underwritten public offering. The company aims to raise a substantial $100.0 million through the sale of its common stock or pre-funded warrants. This move comes as T...

Tarsus Pharmaceuticals Inc

Tarsus Pharmaceuticals Inc Faces Growing Deficit in Latest Financial Report

Tarsus Pharmaceuticals Inc has shown strong improvement in its stock performance, with a significant 19.94% increase over the last month. As a result, the share price has risen by 57.24% during the first quarter of 2024 and is only 2.6% away from reaching its 52-week high of $32.53. These positive stock gains indicate that TARS stock is gaining momentum and investors have confidence in the company's prospects.
One of the key factors contributing to this positive outlook is the successful launch of Tarsus' XDEMVY (lotilaner ophthalmic solution) 0.25%. This treatment for Demodex blepharitis has generated impressive net product sales of $13.1 million in the fourth quarter and $14.7 million in the first four months since its launch. This demonstrates strong market demand and suggests a positive revenue trend for Tarsus.

Clinical Study

Tick-Killing Breakthrough: Tarsus Pharmaceuticals' TP-05 Demonstrates Potential as a Game-Changer in Lyme Disease Prophylaxis

Published Thu, Feb 22 2024 1:00 PM UTC

Tarsus' TP-05 Shows Promising Results in Phase 2a Trial: A Potential Breakthrough in Lyme Disease ProphylaxisLyme disease, caused by the spirochete bacterium Borrelia burgdorferi, is a significant public health concern in many parts of the world, particularly in regions where ticks thrive. It is transmitted to humans primarily through the bite of infected blacklegged ticks (...

Clinical Study

Tarsus Pharmaceuticals' TP-03 Shows Promising Results in Treating Meibomian Gland Disease

Published Mon, Dec 11 2023 1:00 PM UTC

Tarsus Pharmaceuticals Reports Promising Results from Ersa Phase 2a Clinical Trial in Treating Meibomian Gland Disease
Tarsus Pharmaceuticals Inc. recently announced positive topline results from its Ersa Phase 2a clinical trial evaluating TP-03 as a treatment for Meibomian Gland Disease (MGD) in patients with Demodex mites. The study demonstrated statistically significa...






 

Tarsus Pharmaceuticals Inc's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Tarsus Pharmaceuticals Inc does not provide revenue guidance.

Earnings Outlook
Tarsus Pharmaceuticals Inc does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com